Walleye Capital’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-126,526
Closed -$474K – 5990
2026
Q2
$474K Buy
+126,526
New +$483K ﹤0.01% 2796
2024
Q2
– Sell
-85,638
Closed -$187K – 5658
2024
Q1
$187K Buy
+85,638
New +$158K ﹤0.01% 4020
2022
Q2
– Sell
-41,535
Closed -$111K – 2426
2022
Q1
$111K Buy
+41,535
New +$159K ﹤0.01% 1717
2021
Q2
– Sell
-17,345
Closed -$134K – 1369
2021
Q1
$134K Buy
+17,345
New +$137K 0.01% 985
2020
Q1
– Sell
-70,397
Closed -$585K – 1064
2019
Q4
$585K Buy
+70,397
New +$475K 0.04% 607

Other funds holding CTMX

Walleye Capital's CTMX Position: Q3 2026 in Review

Walleye Capital sold out of CytomX Therapeutics (CTMX) in Q3 2026, closing a stake of 126,526 shares — an estimated $474K sold.

Walleye Capital first reported a position in CTMX in Q4 2019 and held it in 5 quarters. The position peaked at $585K in Q4 2019. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Walleye Capital reported no remaining CytomX Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 126,526 CytomX Therapeutics shares in Q3 2026, an estimated $474K.
  • Walleye Capital first reported a position in CytomX Therapeutics in Q4 2019 and held it in 5 quarters.
  • Walleye Capital's CytomX Therapeutics position peaked at $585K in Q4 2019.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.